Study S000068

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

ClinicalTrials.gov record

Registration

Registration: NCT06732245
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 224
Start: 2026-08-15
Primary completion: 2027-08-15
Lead sponsor: Biomed Industries, Inc.
Conditions: Obesity and Overweight
Interventions: DRUG:NA-931; DRUG:Tirzepatide; DRUG:NA-931 150 mg + no Tirzepatide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change from baseline in body weight at 48 weeks [48 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.